Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAVI BioPharma Receives Key Patents for Drug Candidate AVI-6002 Targeting Ebola Zaire Virus Protein VP35
AVI BioPharma, 04/29/09
AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced issuance of the second of two key U.S. patents covering the Company's candidate drug for the treatment of Ebola Zaire infection. The patents titled "Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection" , cover composition and methods to target the Ebola virus VP35 protein with a range of PMOplus compounds. The patents have an expiration date of Oct. 2025.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Epidemiology and Evolution of Invasive Pneumococcal Disease Caused by Multidrug Resistant Serotypes of 19A in the 8 Years After Implementation of Pneumococcal Conjugate Vaccine Immunization in Dallas, Texas
The Pediatric Infectious Disease Journal, 12/17/09
Multidrug resistance protein 3 R652G may reduce susceptibility to idiopathic infant cholestasis
World Journal of Gastroenterology, 12/17/09
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Expert Review of Anti-infective Therapy, 12/17/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor